Tumor
Markers - Global Pipeline Analysis, Competitive Landscape and Market
Forecasts to 2017” provides key data, information and analysis on the
global tumor markers market. The report provides market landscape,
competitive landscape and market trends information on the tumor markers
market. The report provides comprehensive information on the key trends
affecting the market, and key analytical content on the market
dynamics. The report also reviews the competitive landscape and
technology offerings.
While tumor markers have been part of the global cancer diagnostics market since the 1960s, their popularity as therapeutic targets has only risen in the last few decades, primarily due to the increasing prevalence and mortality related to cancer. Cancer is currently the second leading cause of death in most developed countries of the world such as the US, the UK and so on, and is one of the most researched disease areas in the pharmaceutical and biotechnology industry. The global tumor markers market was estimated at $1 billion in 2010 and is expected to grow at a CAGR (compound annual growth rate) of over 6% till 2017. The tumor markers market is poised for rapid growth as researchers approach major technological breakthroughs in tumor diagnosis and therapy, the discovery of new specific antigens, and the genetic basis of cancer. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, the early detection of tumors, and monitoring biological responses to cancer therapy.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
While tumor markers have been part of the global cancer diagnostics market since the 1960s, their popularity as therapeutic targets has only risen in the last few decades, primarily due to the increasing prevalence and mortality related to cancer. Cancer is currently the second leading cause of death in most developed countries of the world such as the US, the UK and so on, and is one of the most researched disease areas in the pharmaceutical and biotechnology industry. The global tumor markers market was estimated at $1 billion in 2010 and is expected to grow at a CAGR (compound annual growth rate) of over 6% till 2017. The tumor markers market is poised for rapid growth as researchers approach major technological breakthroughs in tumor diagnosis and therapy, the discovery of new specific antigens, and the genetic basis of cancer. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, the early detection of tumors, and monitoring biological responses to cancer therapy.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
•Key
geographies covered include the US, Canada, the UK, Germany, France,
Italy, Spain, Japan, China, India, Australia, and Brazil.
•Annualized market revenues data from 2003 to 2010, forecast forward for 7 years to 2017. Company shares data for 2010.
•Qualitative analysis of key market trends, market drivers, and restraints by each category within tumor markers market.
•The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.
•Key players covered include F. Hoffmann-La Roche Ltd, Abbott Laboratories, Fujirebio Inc., bioMérieux SA and Beckman Coulter.
Reasons to buy
•Annualized market revenues data from 2003 to 2010, forecast forward for 7 years to 2017. Company shares data for 2010.
•Qualitative analysis of key market trends, market drivers, and restraints by each category within tumor markers market.
•The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.
•Key players covered include F. Hoffmann-La Roche Ltd, Abbott Laboratories, Fujirebio Inc., bioMérieux SA and Beckman Coulter.
Reasons to buy
•Develop business strategies by understanding the trends and developments that are driving the tumor markers market globally.
•Design and develop your product development, marketing and sales strategies.
•Develop market-entry and market expansion strategies.
•Identify key players best positioned to take advantage of the emerging market opportunities.
•Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
•What’s the next big thing in the tumor markers market landscape? - Identify, understand and capitalize.
•Make more informed business decisions from the insightful and in-depth analysis of the global tumor markers market and the factors shaping it.
•Design and develop your product development, marketing and sales strategies.
•Develop market-entry and market expansion strategies.
•Identify key players best positioned to take advantage of the emerging market opportunities.
•Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
•What’s the next big thing in the tumor markers market landscape? - Identify, understand and capitalize.
•Make more informed business decisions from the insightful and in-depth analysis of the global tumor markers market and the factors shaping it.
For more information, please visit:
Or email us at press@aarkstore.com or call +919272852585
Aarkstore Enterprise
Tel : +912227453309
Mobile No: +919272852585
Email : contact@aarkstore.com
Website : http://www.aarkstore.com
Blog: http://blogs.aarkstore.com/
Follow us on twitter: http://twitter.com/aarkstoredotcom
No comments:
Post a Comment